Former Akero team announces new I&I company, Avere, with China drug

Andrew Cheng, Avere Therapeutics CEO July 14, 2026 06:00 AM EDT DealsChina Af­ter $4.7B sale to No­vo Nordisk, for­mer Akero team an­nounces new I&I com­pa­ny with Chi­na drug Kyle LaHucik Biotech Correspondent Every­thing around Chi­na biotech re­al­ly does seem to be speed­ing up. On Tues­day, the for­mer ex­ec­u­tive team be­hind Akero Ther­a­peu­tics un­veiled a new com­pa­ny, a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER